Post

New research · Endocrinology
Cardiovascular diabetology. Endocrinology reports · 22h
ReviewCardiovascular diabetology. Endocrinology reports · 2026

Concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure.

Reza Khademi, Saeed Shoar
Read paper
EndocrinologyReview

SGLT2 inhibitors reduce heart failure hospitalization and cardiovascular death rates.

Concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure.

Reza Khademi et al. · Cardiovascular diabetology. Endocrinology reports · 2026
Background

Heart failure (HF) is a major cardiovascular complication of type 2 diabetes mellitus (T2DM).

Methods

Emerging data from meta-analyses, subgroup analyses, and observational studies suggest possible additive benefits of combination therapy; however, most evidence is indirect and not derived from dedicated randomized heart failure trials.

Results
SGLT2 inhibitors lower the chance of heart failure hospital stays and heart-related deaths
More results

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) both improve cardiovascular outcomes, but their comparative roles in HF and the potential value of combination therapy remain uncertain.

More results

In contrast, GLP-1 receptor agonists have a more modest effect on HF hospitalization (approximately 11% risk reduction; HR 0.89) while primarily reducing atherosclerotic cardiovascular events and supporting weight and metabolic control.

“
Conclusion · 1 of 2

SGLT2 inhibitors are established therapies for reducing HF outcomes, whereas GLP-1 receptor agonists primarily address cardiometabolic risk with uncertain direct HF benefit.

Conclusion · 2 of 2

Combination therapy is mechanistically plausible but remains insufficiently supported by dedicated randomized evidence in HF populations. Further prospective trials are required to define its clinical role.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
OR 18.90
far higher odds of fatty-liver inflammation with scarring at the top blood-marker level
AI / Informatics
P_adj = 0.038
early pregnancy ANGPTL4 levels were higher in women who developed gestational diabetes
Cohort Study
55.9% vs. 68.1%
Diabetic patients had lower major molecular response at 12 months (55.9% vs 68.1%).
Cohort Study
0.5 %
only 0.5% of blood sugar tests after birth found lasting high blood sugar
Cohort Study
HR 3.05
a high liver risk score means a threefold higher risk of youth type 2 diabetes
Study
HR 1.72
GLP-1 agonists had a 72% greater risk of non-scarring hair loss than DPP-4 inhibitors
Cohort Study
HR 1.095
a higher triglyceride to HDL cholesterol ratio means a higher risk of new diabetes
Case-control
aHR 2.73
BRCA2 gene changes meant a higher risk of cancer getting worse or death